Biotin
FDA-approved product (injectable, injection).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Chronic kidney disease
- Iron deficiency anemia
- Type 2 diabetes mellitus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other plain vitamin preparations
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli19.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis14.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Biotin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
NCT02077751 · start 2013-05
Registered record
- Registry ID
- NCT02077751
- Conditions
- Anemia
- Interventions
- biotin labelled RBCs
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-05
- Completion
- 2019-12
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemiaInterventionbiotin labelled RBCsPhasePhase 1Registry statusCompletedThe Effect of Methylated Vitamin B Complex on Depression
NCT01672372 · start 2011-01
Registered record
- Registry ID
- NCT01672372
- Conditions
- Depression
- Interventions
- Max Stress B; Placebo Max Stress B
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2011-10
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDepressionInterventionMax Stress B; Placebo Max Stress BPhaseNot applicableRegistry statusCompletedDonor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT00988715 · start 2010-04-21
Registered record
- Registry ID
- NCT00988715
- Conditions
- Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts; Secondary Acute Myeloid Leukemia
- Interventions
- Pretargeted Radioimmunotherapy; Cyclosporine; Mycophenolate Mofetil; Total-Body Irradiation; Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Fludarabine Phosphate; Pharmacological Study; Laboratory Biomarker Analysis
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04-21
- Completion
- Not recorded
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia +5 moreInterventionPretargeted Radioimmunotherapy; Cyclosporine; Mycophenolate Mofetil; Total-Body Irradiation +5 morePhasePhase 1Registry statusCompletedEfficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children
NCT00728273 · start 2007-01
Registered record
- Registry ID
- NCT00728273
- Conditions
- Healthy
- Interventions
- worm treatment and multiple micronutrient fortified biscuits
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2007-06
- Enrolment
- 510
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionworm treatment and multiple micronutrient fortified biscuitsPhasePhase 2Registry statusCompletedEnteral Nutrition Support in Children and Adolescents With Cancer
NCT01426750 · start 2002-06
Registered record
- Registry ID
- NCT01426750
- Conditions
- Malnutrition; Cancer
- Interventions
- industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-06
- Completion
- 2006-06
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMalnutrition; CancerInterventionindustrialized oral supplementation (IOS) and tube feeding regimen (TFR) with NutrenPhasePhase 4Registry statusCompleted